HIV Articles
Back
	3 New GSK Integrase Inhibitors in Studies       Early research shows that these drugs are not cross-resistant to raltegravir, Merck integrase but of course further research is needed to confirm this.   1 Completed Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults Condition: HIV-1 Infection Intervention: Drug: GSK364735   2 Active, not recruiting Phase IIa Dose-Ranging Study of GSK1349572 in HIV-1 Infected Adults Condition: HIV-1 Infection Intervention: Drug: GSK1349572   3 Completed A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients Condition: HIV Infections Intervention: Drug: GW810781   4 Recruiting GSK1247303 First Time in Human Study Condition: Healthy Volunteers Intervention: Drug: GSK1247303           View older Articles   Back to Top   www.natap.org